ReviewWorld journal of surgery2007
Evidence-based approach to the management of sporadic medullary thyroid carcinoma.
Review in World journal of surgery, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 77 citations in OpenAlex.
- Long-Term Follow-Up in Medullary Thyroid Carcinoma Patients.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025Review
- Kinetic analysis of the growth rate of sporadic and hereditary medullary thyroid carcinoma: comparing the postoperative calcitonin-doubling rate with the hypothetical preoperative tumor volume-doubling rate.Thyroid research · 2020Article
- Spontaneous Deceleration and Acceleration of Growth Rate in Medullary Thyroid Carcinomas Suggested by Changes in Calcitonin Doubling Times Over Long-Term Surveillance.World journal of surgery · 2019Article
- Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.The Journal of clinical endocrinology and metabolism · 2013Review
- German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.Langenbeck's archives of surgery · 2013Review
- Prognostic and predictive markers in medullary thyroid carcinoma.Endocrine pathology · 2012Article
- Innovative in vitro chemo-hormonal drug therapy for refractory thyroid carcinomas.Journal of Korean medical science · 2012Article
- Painful Hip Leading to the Diagnosis of MEN 2B Syndrome.Case reports in endocrinology · 2012Article
- Medullary Thyroid Cancer: It is a pain in the neck?Journal of Cancer · 2011Article
- Update multiple endocrine neoplasia type 2.Familial cancer · 2010Review
- Adjuvant external beam radiation for medullary thyroid carcinoma.Journal of surgical oncology · 2010Article
- Postoperative complications of thyroid cancer in a single center experience.Journal of Korean medical science · 2010Article
- Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: a molecular guide to the optimal extent of surgery?World journal of surgery · 2010Article
- [Surgery of thyroid carcinoma].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2009Article
- Sporadic and familial medullary thyroid carcinoma: state of the art.The Surgical clinics of North America · 2009Review
- Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma?Langenbeck's archives of surgery · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medullary thyroid carcinoma (MTC) is a rare malignancy of the thyroid C cells. It occurs in hereditary (25% of cases) and sporadic (75%) forms. Sporadic MTCs frequently metastasize to cervical lymph nodes. Thorough surgical extirpation of the primary tumor and nodal metastases by compartment-oriented resection has been the mainstay of treatment (level IV evidence). Surgical resection of residual and recurrent disease is effective in reducing calcitonin levels and controlling complications of central neck disease (level IV evidence). Radioactive iodine, external beam radiation therapy, and conventional chemotherapy have not been effective. Newer systemic treatments, with agents that target abnormal RET proteins hold promise and are being tested in clinical trials for patients with metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.